Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Galera Therapeutics, Inc. (GRTX)
|
Add to portfolio |
|
|
|
| Price: |
$3.96
| | Metrics |
| OS: |
43.9
|
M
| |
|
|
| Market cap: |
$174
|
M
| |
|
|
|
Net cash:
|
$24.2
|
M
| |
$0.55
|
per share
|
|
EV:
|
$150
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($51.1)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
($2.18)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 20.6 |
| Revenue growth | | | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 41.2 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -20.6 |
| Gross margin | | | | | | -100.0% |
| Research and development | 31.0 | 52.4 | 54.8 | 42.3 | 18.7 | |
| General and administrative | 20.2 | 21.0 | 15.7 | 8.4 | 5.6 | 3.5 |
| EBIT | -51.2 | -73.4 | -70.6 | -50.7 | -24.3 | -24.1 |
| EBIT margin | | | | | | -117.0% |
| Pre-tax income | -62.3 | -80.5 | -74.2 | -51.9 | -23.9 | -23.9 |
| Income taxes | -0.1 | 0.0 | 0.0 | 0.0 | -0.2 | -0.4 |
| Tax rate | 0.1% | 0.0% | 0.0% | 0.0% | 0.9% | 1.5% |
| Net income | -62.2 | -80.5 | -74.2 | -59.1 | -29.6 | 0.0 |
| Net margin | | | | | | -0.1% |
| |
| Diluted EPS | ($2.30) | ($3.12) | ($2.98) | ($16.31) | ($98.42) | ($93.59) |
| Shares outstanding (diluted) | 27.1 | 25.8 | 24.9 | 3.6 | 0.3 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|